Diabetic Macular Edema

Intravitreal triamcinolone acetonide, dexamethasone implant superior for regional treatment of disorder

Findings from the PERMEATE study used novel diagnostics to quantify response to intravitreal injections

Combination therapy benefits from laser in the mix for DME, other conditions

Factoring in that patients require continual and constant monitoring, maintenance

A phase II clinical trial evaluating suprachoroidal CLS-TA used with intravitreally administered aflibercept in patients with diabetic macular edema (DME) over a 6-month evaluation period-has met both primary and secondary endpoints of vision and anatomic improvement. 

Compared with intravitreous ranibizumab, the decreases in the plasma-free VEGF levels were greater with intravitreous aflibercept and bevacizumab in patients with diabetic macular edema.